{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The number of participants with significant change in percentage of circulating CD4+ T regulatory cells, marked by expression of FOXP3 after treatment. TGFβ has been implicated in the formation of T regulatory cells, and the blockade of TGFβ in animal models can inhibit the formation of T regulatory cells.","groups":[{"description":"Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment\n\nGC1008: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.","id":"OG000","title":"Investigational Drug infusion-for Safety and Effectiveness"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Outcome analysis presented in manuscript of results of trial based on 13 participants.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Assessment of Systemic TGFβ After Repeated Anti-TGFβ Antibody Installation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}